1,851 results found
    1. Biochemistry and Chemical Biology
    2. Cell Biology

    Subcellular drug targeting illuminates local kinase action

    Paula J Bucko et al.
    Genetically-encoded platforms direct kinase inhibitor drugs to organelles to reveal new dimensions of local kinase signaling.
    1. Cancer Biology
    2. Developmental Biology

    Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

    Carla S Verissimo et al.
    Libraries of patient-derived tumor organoids are a reliable and scalable model system that can help identify and optimize targeted therapies in a pre-clinical setting.
    1. Cancer Biology

    A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer

    Haojie Jin et al.
    Combination of glutaminase inhibitor CB-839 and ASCT2 inhibitor V-9302 showed efficient antitumor effect against glutamine addicted liver cancer cells via glutathione depletion and reactive oxygen species (ROS) induction.
    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease

    Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy

    Joseph Shaw et al.
    Exploiting virus-encoded ion channels as drug targets drove a multi-faceted approach to deriving potent small molecules targeting HCV p7, simultaneously providing new insights into its fundamental biology.
    1. Cell Biology
    2. Computational and Systems Biology

    Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells

    Anil Korkut et al.
    Data-driven systems biology models of signaling predict cellular response to untested perturbations and can nominate drug combinations to overcome drug resistance in cancer cells.
    1. Computational and Systems Biology

    Unravelling druggable signalling networks that control F508del-CFTR proteostasis

    Ramanath Narayana Hegde et al.
    Analysis of the mechanism of action of cystic fibrosis corrector drugs reveals signalling pathways potently controlling the proteostasis of the main disease-relevant CFTR mutant.
    1. Cancer Biology

    MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation

    Seiji Arai et al.
    MARCH5 mediates a pathway driving MCL1 degradation in response to cellular stress, which sensitizes to BH3 mimetic drugs targeting BCLXL and provides a broadly effective therapeutic strategy for solid tumors.
    1. Biochemistry and Chemical Biology
    2. Neuroscience

    Cell type-specific pharmacology of NMDA receptors using masked MK801

    Yunlei Yang et al.
    The small molecule NMDA-receptor antagonist MK801 has been genetically targeted to specific cell types in brain tissue to examine the role of NMDA receptors in cocaine-induced synaptic plasticity.
    1. Cancer Biology

    Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells

    Arun M Unni et al.
    Cancer cells driven by mutations in KRAS or EGFR are dependent on DUSP6 to prevent ERK-induced cell death, creating a novel vulnerability for targeted therapy.
    1. Cancer Biology

    Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer

    Patricia L Theard et al.
    Combined EGFR and SOS1 inhibition synergize to inhibit NSCLC spheroid growth.

Refine your results by:

Type
Research categories